

HR 617

Clinical Trial Cancer Mission 2020 Act

Congress: 114 (2015–2017, Ended)

Chamber: House

Policy Area: Health

Introduced: Jan 28, 2015

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jan 30, 2015)

Official Text: <https://www.congress.gov/bill/114th-congress/house-bill/617>

Sponsor

Name: Rep. Reed, Tom [R-NY-23]

Party: Republican • **State:** NY • **Chamber:** House

Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Slaughter, Louise McIntosh [D-NY-25]	D · NY		Jan 28, 2015
Rep. Brown, Corrine [D-FL-5]	D · FL		Mar 16, 2015

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jan 30, 2015

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Clinical Trial Cancer Mission 2020 Act

Amends the Public Health Service Act to revise clinical trial registry data bank provisions to specify that a device or drug clinical trial must be included in the clinical trial registry data bank regardless of whether it results in a positive or negative outcome.

Requires the responsible party of any clinical trials funded in whole or in part by the Department of Defense (DOD) to certify in all required grant or progress forms that the required submissions to the clinical trial registry data bank have been made. Requires DOD to verify that the clinical trial information has been submitted before releasing any remaining grant funds or funding future grants.

Makes a clinical trial grantee of the Department of Health and Human Services or DOD who fails to submit the required information to the data bank ineligible for the remaining grant funds or future funds. Makes the grantee liable for repayment of grant amounts already provided.

Actions Timeline

- **Jan 30, 2015:** Referred to the Subcommittee on Health.
- **Jan 28, 2015:** Introduced in House
- **Jan 28, 2015:** Referred to the House Committee on Energy and Commerce.